<DOC>
	<DOCNO>NCT01348217</DOCNO>
	<brief_summary>Exclusive concomitant radiochemotherapy ( RCT ) dose 50 Gy deliver 5 week , accord RTOG 85-01 protocol , lead improved 5-year survival 25 % patient , whereas patient survive 5 year use radiotherapy alone patient esophageal cancer . Surgery , even combine preoperative RCT , also give disappointing result locally advanced tumor , cast serious doubt usefulness preoperative radiotherapy . By vary fractionation schedule , length treatment radiotherapy volume , become possible obtain level loco-regional relapse around 35 45 % . After review result loco-regional relapse accord dose radiation recommend radiotherapy volume , aim investigate increase dose radiation impact esophageal cancer . Although INT-0123 phase III trial show benefit dose escalation esophageal cancer , issue remain unclear patient die experimental arm treat 50Gy . Moreover , tumor treat 64Gy involve node consider dose escalation trial . In RTOG 85-01phase III trial , elective nodal irradiation subclavicular fossa esophagogastric junction perform 2D technique , deliver 30Gy could consider appropriate . In randomized phase II/III trial , aim test exclusive concomitant chemoradiotherapy patient non resectable esophageal cancer dose escalation 66Gy primary tumor well involved node use 3D conformal technique combine 40 Gy elective nodal irradiation lymph node station ( define RTOG ) risk microscopic involvement â‰¥ 20 % .</brief_summary>
	<brief_title>Radiochemotherapy With Without Dose Escalation Patients Presenting Locally Advanced Inoperable Carcinoma Oesophagus</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>1 . Age &gt; = 18 &lt; 75 an 2. WHO Status 0 , 1 2 3 . Enteral parenteral feeding ( &gt; = 1500 KCal ) plan start treatment 4 . Histologically proven carcinoma oesophagus 5 . Histological Types : adenocarcinoma epidermoid carcinomas 6 . T3 , N0N1N2N3 , M0 ( TNM version 7 ) 7 . T1T2 , N0N1N2N3 , M0 contraindication surgery ( TNM version 7 ) 8 . Absence tracheaoesophageal fistula 9 . Written inform consent 10 . Woman appropriate contraception 11 . Patient able understand complete , help necessary , quality life questionnaire 1 . Evolutive heart failure myocardial necrosis le 6 month 2 . Myocardial infarction 6 month ischemic sequelae myocardial scintigraphy . 3 . Patient absorb least 1500kcal/j and/or treatment 4 . Left heart failure . 5 . Stage II IV arteriopathy Leriche Fontaine classification 6 . Creatinine &gt; = 1.25x N 7 . PNN &lt; 1,5.109 /l 8 . Platelets &lt; 100 . 109 /l 9 . Albumin &lt; 30g/l 10 . TP &lt; 60 % without anticoagulant 11 . VEMS &lt; 1l 12 . History cancer ( except basocellular cutaneous epithelioma situ epithelioma cervix ) relapse 5 year precede recruitment trial 13 . Patient already enrol another therapeutic trial experimental molecule 14 . Women pregnant likely , breastfeed 15 . People custody guardianship 16 . Impossibility adhere medical follow trial geographical , social psychiatric reason . 17 . Presence history radiotherapy chest upper abdomen another tumour 18 . Peripheral neuropathy &gt; = grade 1 ( CTC v3.0 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>unoperated cancer</keyword>
	<keyword>oesophagus</keyword>
	<keyword>radiochemotherapy</keyword>
	<keyword>without increase dos</keyword>
</DOC>